Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2025-12-26 @ 6:23 PM
Study NCT ID:
NCT05178134
Status:
COMPLETED
Last Update Posted:
2025-08-19
First Post:
2021-12-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
Sponsor:
Scandinavian Biopharma AB
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-08
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-20
Completion Date Type:
ACTUAL
First Submit Date:
2021-12-03
First Submit QC Date:
None
Study First Post Date:
2022-01-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-10-11
Results First Submit QC Date:
None
Results First Post Date:
2025-08-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-15
Last Update Post Date:
2025-08-19
Last Update Post Date Type:
ACTUAL